7:41 PM
 | 
Dec 03, 2012
 |  BC Extra  |  Clinical News

Geron discontinues GRN1005

Geron Corp. (NASDAQ:GERN) discontinued development of GRN1005 after the compound produced no confirmed intracranial responses in a planned interim futility analysis of the first 30 evaluable patients with brain metastases arising from metastatic breast cancer in the Phase II GRABM-B trial. Geron also discontinued the Phase II GRABM-L trial evaluating GRN1005 in patients with brain metastases arising from non-small cell lung cancer (NSCLC). The company...

Read the full 312 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >